drugset / Trial / NCT04372407
A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects
NaSingle-groupOpen-labelBasic science
Summary
This study will be a 2-period study conducted with 14 healthy male or female subjects. Subjects will be administered surufatinib alone in Period 1 and in combination with itraconazole in Period 2.
Timeline
- Start
- 2020-07-09
- Primary completion
- 2020-09-29
- Completion
- 2021-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itraconazole | Small molecule | 200 mg | — |
| Subject | Surufatinib | Small molecule | 200 mg | — |
Indications
No indication recorded.